• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用 I-neb AAD 系统时,呼吸模式对成人囊性纤维化患者妥布霉素血清水平的影响。

The influence of breathing mode on tobramycin serum levels using the I-neb AAD system in adults with cystic fibrosis.

机构信息

Central Hospital Pharmacy, The Hague, The Netherlands; Department of Clinical Pharmacology, Haga Teaching Hospital, The Hague, The Netherlands.

Central Hospital Pharmacy, The Hague, The Netherlands; Department of Clinical Pharmacology, Haga Teaching Hospital, The Hague, The Netherlands.

出版信息

J Cyst Fibros. 2015 Nov;14(6):748-54. doi: 10.1016/j.jcf.2015.01.002. Epub 2015 Jan 27.

DOI:10.1016/j.jcf.2015.01.002
PMID:25636858
Abstract

BACKGROUND

The clinical effectiveness of inhaled tobramycin depends on the dose reaching the desired regions of the lungs. This study evaluates the influence of breathing mode on tobramycin lung deposition using its pharmacokinetics as surrogate for deposition.

METHODS

In a randomized, open-label, crossover study lung deposition in 18 adult CF patients is evaluated following inhalation of tobramycin aerosol using the I-neb nebulizer with TBM (Tidal Breathing Mode) and TIM (Target Inhalation Mode) breathing patterns. Breathing in TIM forced the patient to inhale in a slow and deep manner. Patients were categorized in three subgroups according to their lung function: ≤59%, 60-79% or ≥80% of FEV1 predicted. Blood samples were collected in order to model tobramycin pharmacokinetics. Nebulization time was recorded.

RESULTS

Inhalation with TIM resulted in significantly higher maximum serum levels and area under the concentration-time curves (0-24h). Mean bioavailability of TIM relative to TBM was 1.53±0.41. Mean nebulization time was reduced by half with TIM. Subgroup category did not affect the results.

CONCLUSIONS

Slow and deep inhalation of aerosolized tobramycin resulted in higher lung deposition and shorter nebulization time compared to tidal breathing, regardless of the disease severity of the CF patient. Dutch trial register number NTR3109.

摘要

背景

吸入妥布霉素的临床疗效取决于到达肺部目标区域的剂量。本研究通过其药代动力学作为沉积的替代物来评估呼吸模式对妥布霉素肺部沉积的影响。

方法

在一项随机、开放标签、交叉研究中,使用 I-neb 雾化器,通过 TBM(潮式呼吸模式)和 TIM(目标吸入模式)呼吸模式,评估了 18 例成年 CF 患者吸入妥布霉素气雾剂后的肺部沉积情况。TIM 中的呼吸迫使患者以缓慢而深入的方式吸入。根据其肺功能将患者分为三组:FEV1 预测值的 ≤59%、60-79%或 ≥80%。采集血样以建立妥布霉素药代动力学模型。记录雾化时间。

结果

TIM 吸入导致的最大血清水平和浓度-时间曲线下面积(0-24 小时)显著升高。TIM 相对于 TBM 的平均生物利用度为 1.53±0.41。TIM 使雾化时间缩短了一半。亚组类别不影响结果。

结论

与潮式呼吸相比,无论 CF 患者的疾病严重程度如何,吸入雾化妥布霉素时缓慢而深入的呼吸都会导致更高的肺部沉积和更短的雾化时间。荷兰试验注册号 NTR3109。

相似文献

1
The influence of breathing mode on tobramycin serum levels using the I-neb AAD system in adults with cystic fibrosis.使用 I-neb AAD 系统时,呼吸模式对成人囊性纤维化患者妥布霉素血清水平的影响。
J Cyst Fibros. 2015 Nov;14(6):748-54. doi: 10.1016/j.jcf.2015.01.002. Epub 2015 Jan 27.
2
Lung Deposition of Alpha1-Proteinase Inhibitor (Human) (A1-PI[H]) Inhalation Solution Using Two Inhalation Modes of the I-neb Adaptive Aerosol Delivery (AAD) System in Healthy Subjects and Subjects with Cystic Fibrosis.在健康受试者和囊性纤维化受试者中,使用I-neb自适应气雾剂递送(AAD)系统的两种吸入模式时,α1-蛋白酶抑制剂(人)(A1-PI[H])吸入溶液在肺部的沉积情况。
J Aerosol Med Pulm Drug Deliv. 2016 Jun;29(3):242-50. doi: 10.1089/jamp.2014.1173. Epub 2015 Dec 15.
3
Pharmacokinetics and Tolerability of Once Daily Double Dose Tobramycin Inhalation in Cystic Fibrosis Using Controlled and Conventional Nebulization.使用对照和传统雾化方式的每日一次双倍剂量妥布霉素吸入疗法在囊性纤维化患者中的药代动力学及耐受性研究
J Aerosol Med Pulm Drug Deliv. 2016 Jun;29(3):273-80. doi: 10.1089/jamp.2015.1259. Epub 2015 Dec 30.
4
Mode of breathing-tidal or slow and deep-through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of (99m)Tc-DTPA.通过 I-neb 自适应雾化输送(AAD)系统进行的呼吸模式——潮汐式或缓慢而深沉——会影响(99m)Tc-DTPA 在肺部的沉积。
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S37-43. doi: 10.1089/jamp.2009.0786.
5
Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use? Comparison of the CR60 to the PortaNeb compressor.使用PARI LC PLUS可重复使用雾化器雾化妥布霉素(TOBI):应使用哪种压缩机?CR60与PortaNeb压缩机的比较。
J Aerosol Med Pulm Drug Deliv. 2008 Sep;21(3):269-80. doi: 10.1089/jamp.2007.0674.
6
Domiciliary experience of the Target Inhalation Mode (TIM) breathing maneuver in patients with cystic fibrosis.囊性纤维化患者目标吸入模式(TIM)呼吸操的家庭体验。
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S45-54. doi: 10.1089/jamp.2009.0777.
7
A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI.一种高浓度妥布霉素溶液与TOBI的药代动力学及安全性比较。
J Aerosol Med Pulm Drug Deliv. 2014 Jun;27(3):185-92. doi: 10.1089/jamp.2012.1022. Epub 2013 Jun 22.
8
Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.雾化妥布霉素在囊性纤维化患儿中使用 I-neb 和 PARI-LC Plus 的药代动力学和安全性:一项随机、交叉研究。
Br J Clin Pharmacol. 2019 Sep;85(9):1984-1993. doi: 10.1111/bcp.13988. Epub 2019 Jul 10.
9
Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.采用PARI eFlow快速雾化器给药的妥布霉素在囊性纤维化患者中的药代动力学及安全性
J Cyst Fibros. 2009 Sep;8(5):332-7. doi: 10.1016/j.jcf.2009.07.001. Epub 2009 Aug 3.
10
The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation.I-neb 自适应雾化输送系统通过控制吸入提高α1-抗胰蛋白酶的输送。
J Aerosol Med Pulm Drug Deliv. 2010 Apr;23 Suppl 1(Suppl 1):S55-9. doi: 10.1089/jamp.2009.0793.

引用本文的文献

1
Nebuliser systems for drug delivery in cystic fibrosis.雾化器系统在囊性纤维化中的药物输送。
Cochrane Database Syst Rev. 2023 Nov 9;11(11):CD007639. doi: 10.1002/14651858.CD007639.pub3.
2
Comparison of Aerosol Deposition Between a Cynomolgus Macaque and a 3D Printed Cast Model of the Animal.恒河猴与动物 3D 打印模型间气溶胶沉积的比较。
Pharm Res. 2023 Mar;40(3):765-775. doi: 10.1007/s11095-022-03466-w. Epub 2023 Jan 18.
3
Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.
抗生素治疗囊性纤维化患者的药代动力学和药效学优化:当前证据、知识空白和未来方向。
Clin Pharmacokinet. 2021 Apr;60(4):409-445. doi: 10.1007/s40262-020-00981-0. Epub 2021 Jan 24.
4
Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.雾化妥布霉素在囊性纤维化患儿中使用 I-neb 和 PARI-LC Plus 的药代动力学和安全性:一项随机、交叉研究。
Br J Clin Pharmacol. 2019 Sep;85(9):1984-1993. doi: 10.1111/bcp.13988. Epub 2019 Jul 10.